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ABSTRACT
Objective: To estimate the long-term cost-effectiveness of using continu-
ous subcutaneous insulin infusion (CSII) compared with multiple daily
injections (MDI) of insulin in adult and child/young adult type 1 diabetes
mellitus (T1DM) patients from a third-party payer perspective in the
United States.
Method: A previously validated health economic model was used to deter-
mine the incremental cost-effectiveness ratio (ICER) of CSII compared
with MDI using published clinical and cost data. The primary input
variable was change in HbA1c, and was assumed to be an improvement of
-0.9% to -1.2% for CSII compared with MDI for child/young adult and
adults, respectively. A series of Markov constructs simulated the progres-
sion of diabetes-related complications.
Results: CSII was associated with an improvement in quality-adjusted
life-years (QALYs) gained of 1.061 versus MDI for adults and 0.799
versus MDI for children/young adults. ICERs were $16,992 and $27,195
per QALY gained for CSII versus MDI in adults and children/young adults,
respectively. Improved glycemic control from CSII led to a lower incidence
of diabetes complications, with the most signiﬁcant reduction in prolifera-
tive diabetic retinopathy (PDR), end stage renal disease (ESRD), and
peripheral vascular disease (PVD). The number needed to treat (NNT) for
PDR was nine patients, suggesting that only nine patients need to be
treated with CSII to avoid one case of PDR. The NNT for ESRD and PVD
was 19 and 41, respectively.
Conclusions: Setting the willingness to pay at $50,000/QALY, the analysis
demonstrated that CSII is a cost-effective option for patients with T1DM
in the United States.
Keywords: cost-effectiveness analysis, continuous subcutaneous insulin
injection, multiple daily injections, type 1 diabetes mellitus.
Introduction
Type 1 diabetes mellitus (T1DM) is an autoimmune disease
where the insulin-secreting beta cells from the pancreas are
destroyed and the person is unable to produce insulin [1]. The
current standard of care for patients with T1DM includes inten-
sive multiple daily injections (MDI) of insulin or administration
of insulin through medical device technologies referred to as
continuous subcutaneous insulin infusion (CSII), with some
T1DM patients still treated with conventional insulin therapy.
More speciﬁcally, MDI requires at least three premeal injections
of rapid-acting insulin per day, whereas CSII offers continuous or
intermittent delivery of subcutaneous infusions of insulin in very
small amounts, with adjustments in the delivery rate or dose size
when necessary.
The goal of diabetes treatments is to regulate circulating
blood glucose levels and achieve a near normal glycemia.
Hypoglycemia, or less than adequate levels of glucose in the
blood, can occur as a complication of treatment of diabetes
with insulin and can range from moderate (headache) to severe
(coma). In cases of moderate to severe hypoglycemia, hospital-
ization may be necessary, in which costs can accrue. Reducing the
risk of such complications from diabetes both in the near and
distant future is essential for improving the patient’s health-
related quality of life (HRQOL).
Evidence from comprehensive reviews and meta-analyses has
shown that CSII is associated with improved glycemic control
and fewer hypoglycemic events compared with MDI. The
improved glycemic control found with CSII may be because of a
“more physiological” means of insulin delivery using rapid-
acting insulin analogs accurately administered at rates speciﬁ-
cally tailored to patient lifestyles and needs [2,3]. Nevertheless,
CSII requires more equipment and training at initiation than
MDI and thus tends to be more expensive on a short-term basis.
Because of health-care constraints in the United States and
multiple effective treatment options, it is becoming more impor-
tant that decision-makers identify cost-effective interventions for
use in treating T1DM. A recent study by Cohen and colleagues
examined the cost-effectiveness of CSII with MDI in adults and in
children/young adults with T1DM in Australia [4]. Their ﬁndings
suggest that CSII represents good value for money in Australia. A
similar study performed by Roze et al. in the United Kingdom
also found that CSII was a cost-effective treatment option for
patients with T1DM [5]. The objective of this study was to
project long-term cost-effectiveness of CSII compared with MDI
of insulin in adults and in children/young adults with T1DM
using published clinical and cost data from the United States. A
modeling analysis using the previously published and validated
CORE Diabetes Model was the method for evaluation.
Methods
CORE Diabetes Model
A brief overview of the CORE Diabetes Model (CDM) is pro-
vided below; however, previous articles have outlined more spe-
ciﬁcally the structure, data inputs, and validation studies for the
CDM [6,7]. The CDM is a computer simulation model that was
developed to estimate the long-term clinical and economic
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consequences of interventions for T1DM and type 2 diabetes
mellitus (T2DM). The model is a nonproduct-speciﬁc diabetes
policy analysis tool that performs real time simulations while
taking into account intensive or conventional insulin therapy,
oral hypoglycemic medications, screening and treatment strate-
gies for microvascular complications, treatment strategies for
end-stage complications, and multifactorial interventions. The
model is based on a series of submodels that simulate the major
complications of diabetes (angina, myocardial infarction [MI],
congestive heart failure, stroke, peripheral vascular disease,
diabetic retinopathy, macular edema, cataract, hypoglycemia,
ketoacidosis, lactic acidosis, nephropathy and end-stage renal
disease, neuropathy, foot ulcers, amputation, and nonspeciﬁc
mortality). Each submodel is Markov-based and utilizes Monte
Carlo simulation with tracker variables, which uses time, state,
and diabetes type-dependent probabilities derived from pub-
lished sources such as the Diabetes Control and Complications
Trial (DCCT) and UK Prospective Diabetes Study [8,9].
The CDM was designed and programmed by experienced
diabetes disease modelers from IMS-Health along with clinicians
and endocrinologists with superior knowledge of the published
clinical and epidemiological research. For additional details on
CDM, please see Palmer et al. [6].
Adult Cohort Description
Theoretical cohorts of 1000 adult T1DM patients were deﬁned
with baseline demographics, risk factors, and preexisting compli-
cations taken predominantly from the DCCT secondary interven-
tion cohort and are completely summarized and referenced in
Table 1 [3,9]. Brieﬂy, the adult cohort had a mean age of 27.0
years, mean duration of diabetes was 9.0 years, 53.5%were male,
90%were Caucasian, 5%African American, 5%Hispanic, mean
body mass index (BMI) was 23.75 kg/m2, and mean HbA1c was
8.95%. Patient management data for adults were taken from
published epidemiological data in a variety of settings (Table 1).
Child/Young Adult Cohort Description
The child/young adult cohort was deﬁned with baseline demo-
graphics, risk factors, and preexisting complications taken from
Doyle (2004) and the DCCT secondary intervention cohort
(summarized in Table 1) [3,9,10]. The child/young adult cohort
was deﬁned with baseline characteristics of a mean age of 13.0
years (range of 8–21 years) and mean duration of diabetes equal
to 5.6 years, 50% were male, 81.25% were Caucasian, 6.25%
were African-American, 12.5% Hispanic, mean BMI was
23.75 kg/m2, and mean HbA1c was 8.2% [10]. Patient manage-
ment data for children/young adults were taken from published
epidemiological data in a variety of settings (Table 1).
Intervention: CSII versus MDI (Adults)
Weissberg-Benchell et al. published a meta-analysis of insulin
pump therapy in 2003 [3]. The meta-analysis took into account
52 studies with over 1500 patients and was able to quantify and
Table 1 Baseline characteristics of the US adult and child/young adult type 1 diabetes patient cohorts
Characteristic
Adult cohort baseline
value (reference)
Child/young adult cohort
baseline value* (reference)
Patient demographics
Mean age (Years) 27.0 [32] 13.0 [10]
Duration of diabetes (Years) 9.0 [32] 5.6 [10]
Proportion male (%) 53.5% [32] 50.0% [10]
Risk factors
HbA1c (%) 8.95% [32] 8.2% [10]
Systolic blood pressure (mmHg) 115 [32] 115 [32]
Body mass index (kg/m2) 23.75 [32] 23.75 [32]
Total cholesterol (mg/dl) 178.5 [32] 178.5 [32]
High-density lipoprotein cholesterol (mg/dl) 49.0 [32] 49.0 [32]
Low-density lipoprotein cholesterol (mg/dl) 112.0 [32] 112.0 [32]
Triglycerides (mg/dl) 87.0 [32] 87.0 [32]
Ethnic group
Caucasian 90% [32] 81.25% [10]
African American 5% [32] 6.25% [10]
Other 5% [32] 12.5% [10]
Cardiovascular disease (CVD)
Angina pectoris 1.9% [32] 1.9% [32]
Stroke 0.0% 0.0%
Myocardial infarction 0.0% 0.0%
Congestive heart failure 0.0% 0.0%
Atrial ﬁbrillation 3.0% [32] 3.0% [32]
Left ventricular hypertrophy detected by ECG 3.0% [32] 3.0% [32]
Peripheral vascular disease 0.0% 0.0%
Renal disease
Microalbuminuria 10.0% [32] 10.0% [32]
Retinopathy
Background diabetic retinopathy 100% [32] 100% [32]
Patient management of type 1 diabetes
Taking ACE-I/ARB: primary prevention 43.0% [32]
Taking statins: primary prevention 33.0% [32]
Taking aspirin: primary prevention 40.0% [32]
Screened for retinopathy (assumed to be treated with laser if detected) 74.0% [32]
Screened for renal disease (assumed to be treated with ACE-I or ARB if detected) 55.0% [32]
Screened for foot disease 87.0% [32]
*The parameter values for the children/young adult cohort are a combination of values from Doyle et al. [10] and assumptions made from applying the DCCT secondary (intensive) treatment
cohort.
ACE-I, angiotensin-converting enzyme inhibitor;ARB, angiotensin II receptor blockers; DCCT, Diabetes Control and Complications Trial; ECG, electrocardiogram.
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highlight key differences between CSII and MDI therapies in
a comprehensive manner. CSII treatment was associated with
improved HbA1c levels and increased body weight. Based on
the meta-analysis, treatment with CSII for 1 year or greater
was associated with a mean decrease in baseline HbA1c of
1.2%  0.2%, and a mean increase in BMI of 1.03 kg/m2 com-
pared with MDI therapy. These data were used as the base case
comparison for the adult population in the present study with
two other HbA1c values used in the sensitivity analysis (see
Sensitivity Analysis).
Data from an observational study published by Linkeschova
et al., reviews of outpatient insulin therapy in T1DM by DeWitt
and Hirsh, and Bode et al., along with a study by Bruttomesso, all
suggest that hypoglycemia rates are not the same for CSII and
MDI [11–14]. Bruttomesso et al. suggested that CSII reduces
hypoglycemia rates by as much as 74% compared with MDI, and
a similar reduction was observed in an observational study
reported by Linkeschova et al. [11,12]. Therefore, for the adult
base case analysis, we assumed that hypoglycemia event rateswere
50% lower in the CSII group than in the MDI group (CSII event
rate [age < 18] = 42.8657/100 patient-years; CSII event rate
[age > 18] = 28.4492/100 patient years; MDI event rate
[age < 18] = 85.7315/100 patient-years; MDI event rate [age >
18] = 56.8985). To test this assumption, additional sensitivity
analyses were performed, assuming no difference in hypoglycemia
rates betweenCSII andMDI and also a 75% reduction in hypogly-
cemia for the CSII treatment arm compared with MDI.
Intervention: CSII versus MDI (Children/Young Adults)
Doyle and colleagues performed a randomized, prospective trial
in children and young adults with T1DM, comparing the efﬁcacy
of CSII with MDI using insulin glargine [10]. Patients were
assigned to receive either MDI treatment with once-daily glargine
and premeal/snack insulin aspart or CSII with insulin aspart [10].
This study was the ﬁrst direct evaluation of CSII and glargine-
based analogue MDI therapy in youth with T1DM using a ran-
domized, prospective study design and a short time frame. The
study found that lower HbA1c and premeal glucose levels were
more achievable with CSII than with glargine-based analogue
MDI treatment, and that CSII is an efﬁcacious treatment to
improve metabolic control in children/young adults with T1DM.
Speciﬁcally, over a 16-week period, the study found a mean
decrease in HbA1c of 0.9%  0.2% (P < 0.01) for patients
treated with CSII and a mean decrease in HbA1c of 0.1%  0.1%
for patients treated with MDI. These data were used as the base
case comparison for the child/young adult population in the
present study, with two other HbA1c values used in the sensitivity
analysis (see Sensitivity Analysis).
Similar to the adult base case analysis, in the child/young
adult base case analysis, we assumed that hypoglycemia event
rates were 50% lower in the CSII group than in the MDI group
(see rates above for adults) [11–14]. In addition, sensitivity
analysis were run using the same hypoglycemia event rates in
both groups and reducing hypoglycemia event rates even further
(75%) (see Sensitivity Analysis) [9].
Costs, Perspective, and Utility Values
The perspective for our analyses was that of a third-party US
payer. All costs were expressed in 2007 US dollars. Costs of
concomitant medications and diabetes-related complications
were taken from published sources and inﬂated to 2007 US
dollars and summarized in Table 2 [15]. The cost for diabetic
complications largely arise from studies in T2DM populations.
This is because of the number of studies in complications that
come from T2DM populations compared with almost no analo-
gous studies in T1DM populations. Therefore, our study utilized
diabetes complication costs largely from T2DM populations,
which are a potential limitation of our study.
Annual costs of CSII and MDI were based on pump costs
(assuming 7-year pump life before replacement is needed in the
base case), insulin costs, consumable supplies, self-monitoring of
blood glucose, and outpatient costs. We assumed that 28% of
MDI users in the United States use pen devices and inject four
times per day (Medtronic data on ﬁle). We also assumed that CSII
users change the reservoirs and infusion sets every 3 days (deﬁned
as Consumables in Table 3). These costs are fully itemized for US
T1DM adult and child/young adult patients in Table 3.
The health state utilities and disutilities used in the analyses
were taken from previously published studies as described in
Table 4 [16–19]. In cases where no published state-speciﬁc health
utilities were identiﬁed, it was conservatively assumed that the
utility value was equivalent to a T1DM patient with no diabetes
complications. This assumption was applied to the following
health states: microalbuminuria, gross proteinuria, background
diabetic retinopathy, and healed foot ulcer.
Time Horizon and Discounting
The time horizon for the simulation was set to 60 years to
capture the remainder of a T1DM patient’s lifetime consistent
Table 2 Cost per diabetes complication or event, adjusted to $US 2007
[15]
Description of event or state
Adjusted diabetes
complication
costs ($US 2007)* Reference
Myocardial infarction, year of event $38,783.33 [25]
Myocardial infarction, each subsequent year $2,143.85 [25]
Angina, year of onset $7,694.28 [25]
Angina, each subsequent year $1,987.16 [25]
Congestive heart failure, year of onset $3,331.62 [25]
Congestive heart failure, each
subsequent year
$3,331.62 [25]
Stroke, year of event $51,359.50 [25]
Stroke, each subsequent year $17,140.63 [25]
Peripheral vascular disease, onset $4,878.19 [33]
End-stage renal disease $47,298.92 [25]
Laser treatment $864.13 [25]
Severe vision loss/blindness, ﬁrst year $4,185.53 [25]
Severe vision loss/blindness, each
subsequent year
$4,184.49 [25]
Cataract extraction $2,751.35 [33]
Neuropathy, onset $422.41 [25]
Uninfected ulcer (monthly based) $1,833.87 [34]
Infected ulcer (monthly based) $3,314.58 [34]
Gangrene (monthly based) $6,466.78 [34]
Amputation, year of event $34,204.23 [25]
Amputation, each subsequent year $1,229.04 [25]
Major hypoglycemic event $1,234.31 [21]
Ketoacidosis $13,891.96 [25]
Annual cost aspirin $23.85 [35]
Annual cost statins (assume simvastatin
10 mg at 238/100 tablets, inﬂated
to $US 2007)
$982.23 [35]
Annual costs angiotensin converting
enzyme inhibitor (based on 25-mg
captopril tris in diem)
$441.72 [36]
Costs of screening for retinopathy $85.17 [22]
Costs of screening for microalbuminuria $19.30 [22]
Costs of screening for gross proteinuria $28.40 [22]
Costs (monthly) nonstandard ulcer
treatment (Regranex, Ethicon,
Somerville, NJ, USA)
$173.74 [37]
*Diabetes complication costs largely arise from T2DM populations and not T1DM popula-
tions as there are few if any diabetes complication cost data available forT1DM populations.
T1DM, type 1 diabetes mellitus;T1DM, type 2 diabetes mellitus.
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with diabetes modeling guidelines that recommend time horizons
be sufﬁcient to include the development of all relevant compli-
cations [20]. In the base case analysis, a discount rate of 3.0%
per annum was applied to both costs and clinical outcomes in
line with current recommendations in the US setting [20]. Dis-
counting is a standard economic principle based on the hypoth-
esis that future costs and events are worth less than current costs
and events.
Sensitivity Analysis
Sensitivity analyses were performed to test the robustness of our
results in adult and child/young adult US patients with T1DM.
The ﬁrst sensitivity analysis for adults varied the treatment effects
on HbA1c by using the overall HbA1c lowering effects of
(-0.95%  0.15%) from the Weissberg-Benchell meta-analysis
for all CSII users, regardless of treatment duration [3]. The
second sensitivity analysis for adults varied the treatment effects
on HbA1c by (-0.51%  0.24%) because of ﬁndings from an
earlier meta-analysis by Pickup et al. [2]. In child/young adult
patients, a sensitivity analysis was performed in which the base
case treatment effect for HbA1c for the CSII treatment arm was
increased and decreased by 25% from the base case of 0.9% (i.e.,
-1.125% and -0.675%).
Next, based on new data from published reviews, an obser-
vational study, and meta-analyses, we assumed for the base case
analysis for adults and children/young adults that hypoglycemia
event rates were 50% lower in CSII than in MDI [11–14]. To test
these assumptions, we performed additional sensitivity analyses
reducing the hypoglycemia event rates by 0% and 75% in the
CSII treatment arm to show the results for no difference between
groups and a larger difference between groups. We also per-
formed a sensitivity analysis on the cost of severe hypoglycemia.
For the base case, we assumed the costs to be $1234.31 [21], butTa
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Table 4 Utility/disutility values used in the comparison between CSII
and MDI for United States
Event/state Utility/disutility† Reference
Diabetes, no complications 0.814 [16]
Angina 0.682 [16]
Congestive heart failure 0.633 [16]
Myocardial infarction, year of event -0.129 [16]
Myocardial infarction, years 2+ following event 0.736 [16]
Stroke, year of event -0.181 [16]
Stroke, years 2+ following event 0.545 [16]
Peripheral vascular disease 0.570 [17]
Microalbuminuria 0.814 *
Gross proteinuria 0.814 *
Hemodialysis 0.49 [17]
Peritoneal dialysis 0.56 [17]
Kidney transplant 0.762 [17]
Background diabetic retinopathy 0.814 *
Cataract 0.794
Macular edema 0.794
Proliferative diabetic retinopathy 0.794
Severe vision loss/blindness 0.734 [16]
Neuropathy 0.624
Active ulcer 0.600 [18]
Healed diabetic ulcer 0.814 *
Amputation, year of event -0.109 [16]
Amputation, years 2+ following event 0.68 [16]
All hypoglycemic events -0.0052 [19]
*No state-speciﬁc health utility identiﬁed—conservatively assumed to be equivalent
to complication-free utility, 0.020 = disutility for mild vision loss, 0.190 = disutility for
neuropathy.
†Diabetes health state utilities largely arise from T2DM populations and not T1DM popula-
tions, as there are few, if any, diabetes health state utility data available forT1DM populations.
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections;T1DM, type 1
diabetes mellitus; T1DM, type 2 diabetes mellitus.
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because of the uncertainty surrounding this value and ﬁndings
from O’Brien and colleagues, which suggest a much lower value,
we performed a sensitivity analysis utilizing the cost of $273.89
as well [22].
Additional sensitivity analyses included varying the discount
rates on costs and clinical outcomes using 0% and 6% in adult
and child/young adult US patients with T1DM and a change in
BMI equal to 0 and 1.59 in adults. Further, we considered
replacement of an insulin pump every 4, 6 and 8 years instead of
the base case assumption of a 7-year pump life to make our
analyses more comprehensive. It was assumed that payers would
not replace a pump any earlier than 4 years because the warranty
is only 4 years; thus exploring the cost-effectiveness for less than
4 years was not performed.
We performed a sensitivity analysis on the fear of hypoglyce-
mia in adult and children/young adult patients with T1DM based
on a study by Currie and colleagues, which addressed a disutility
because of a fear of hypoglycemia associated with hypoglycemic
events [23]. In our analysis, a lower number of episodes of severe
hypoglycemia were assumed in patients taking CSII. Therefore,
there may be an annual improvement in quality of life (QOL)
compared with those taking MDI because of an annual reduc-
tion in the fear of hypoglycemia (fear of hypo disutility per
event ¥ number of hypo events). A sensitivity analysis was run
using the QOL disutility rate associated with a severe hypogly-
cemic event (4.7%; Currie et al.), and was adjusted based on the
annual number of severe hypoglycemia events in the two treat-
ment groups, (14 events/100 patients/year in the CSII group and
62 events/100 patients/year in the MDI group), providing an
overall annual reduction in utility of -0.00658 (4.7% ¥ 0.14) in
the CSII arm and -0.02914 (4.7% ¥ 0.62) in the MDI group.
Thus, an annual difference in QOL of 0.023 (-0.00658 -
[-0.02914]) was compared between the two groups to determine
whether QOL was affected.
Finally, in the base case analysis for both adults and children/
young adults, the QOL utilities for major hypoglycemia event
and for all hypoglycemia event were based on ﬁndings from the
National Institute for Clinical Excellence study (QOL for major
event = -0.0121 and QOL for all events = -0.0052) [19]. Nev-
ertheless, based on more recent ﬁndings from Currie and col-
leagues, these values may differ slightly. Therefore, sensitivity
analyses were run using QOL utilities from the Currie study to
determine how these differences may affect the study outcomes.
The Currie values were as follows: (QOL for major event =
-0.0118 and QOL for all events = -0.0035) [23].
Statistical Analysis
To evaluate the uncertainty in the estimated cost-effectiveness
and clinical outcomes from this analysis, nonparametric resam-
pling methods, incorporating the updated methodology from
Halpern et al., were used [24]. All of the probabilities that were
used in the CDMwere initially sampled using a ﬁrst-order Monte
Carlo simulation approach, which provided a point estimate for
each parameter. These point estimates were then used in a
second-order Monte Carlo simulation approach. The resampling
method was then applied to each parameter from the ﬁrst-order
Monte Carlo results with costs and outcomes accumulated for
1000 theoretical patients, each going through the model 1000
times, resulting in a joint distribution of mean incremental costs
and effectiveness gained. The percentages of joint distributions
falling within a cost-effective range were calculated with these
data and used to plot a cost-effectiveness acceptability curve and
scatter plots. This type of statistical approach can be considered
equivalent to repeating the same clinical trial multiple times.
Therefore, this method is intended to provide information on the
uncertainty surrounding outcomes data simulated through the
CDM [7].
Results: Adult T1DM Patients in the
United States
Life Expectancy (LE) and Quality-Adjusted
Life Expectancy
In the base case analysis, T1DM treatment with CSII was
projected to improve discounted LE and quality-adjusted life-
years gained (QALYs) by 0.987 and 1.061 years, respectively,
compared with MDI. Mean (SD) discounted LE was
18.874  0.231 years for CSII and 17.888  0.169 years with
MDI. Mean (SD) discounted QALYs were 12.848  0.197
years for CSII and 11.788  0.107 years with MDI (see Table 5).
Calculation of undiscounted LE produced values of 30.753 
0.231 years in the CSII group and 28.287  0.169 years in the
MDI arm (a difference of 2.466 years). Calculation of undis-
counted QALYs produced values of 20.318  0.197 years in the
CSII group and 18.153  0.107 years in the MDI arm (a differ-
ence of 2.165 QALY).
Incidence of Complications
Improved glycemic control associated with CSII treatment com-
pared with MDI led to a lower incidence of several key compli-
cations from diabetes over patients’ lifetimes. In regard to eye
disease, the cumulative incidence of proliferative diabetic retin-
opathy was reduced by 29% compared with MDI over the
60-year simulation period (relative risk [RR] = 0.71). The corre-
sponding number needed to treat (NNT) for proliferative dia-
betic retinopathy was nine patients, suggesting that only nine
patients need to be treated with CSII to avoid one case of pro-
liferative diabetic retinopathy. In regard to end-stage renal
disease (ESRD), the cumulative incidence of ESRD was reduced
by 20% compared with MDI over the 60-year simulation period
(RR = 0.80). Similarly, the cumulative incidence of neuropathy
death was reduced by 22% compared with MDI (RR = 0.78).
Corresponding NNT for ESRD and neuropathy death was 19
Table 5 Summary results for adult type 1 diabetes patients in the United States: CSII versus MDI base case
CSII MDI
Difference between
CSII and MDI
Life expectancy (years) 18.874 0.231 17.888 0.169 0.987
Quality-adjusted life expectancy (years) 12.848 0.197 11.788 0.107 1.061
Total direct costs ($US 2007) $204,192 2,950 $186,170 3,159 $18,023
Costs/life expectancy ($US 2007 per life-year gained) $18,268
Costs/QALY ($US 2007 per QALY gained) $16,992
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections; QALY, quality-adjusted life-year.
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and 21, respectively. Finally, the ﬁndings for cardiovascular com-
plications showed that the cumulative incidence of peripheral
vascular disease was reduced by 16% compared with MDI over
the 60-year simulation period (RR = 0.84), with a NNT of 41
patients. Additional observations for diabetes complications are
shown in Table 6.
Costs and Cost-Effectiveness
The mean discounted lifetime direct medical costs associated
for T1DM with CSII in US adults was projected to be
$US204,192  2,950 compared with $US186,170  3,159 for
MDI treatment (see Table 5). The incremental difference in costs
of $US18,023 translates into a cost per life-year gained (LYG) of
$US18,268 with CSII therapy versus MDI. The cost per QALY
gained was $US16,992. The resampling simulation data were
placed on a scatter plot based on QALYs gained and included as
Figure 1. The data were then plotted on an acceptability curve to
assess the likelihood of cost-effectiveness according to willingness
to pay in the United States. Setting the willingness to pay at
$US50,000/QALY, the analysis demonstrated that CSII had a
100% probability of being cost-effective for adult T1DM using
QALYs gained as the outcome measure (see Fig. 2).
The breakdown of total direct medical costs showed that
treatment costs were the greatest component. Mean lifetime
treatment costs were $US103,386 in the CSII group compared
with $US69,247 for MDI. Complication and other management
costs were $US16,117 lower for CSII compared with MDI
($US100,806 vs. $US116,923, respectively). Therefore, the extra
treatment costs associated with CSII were partially offset by the
reduction in diabetes complications compared with MDI, even
when taking into account the survival paradox (that patients live
longer with CSII treatment, and therefore should experience
more complications and incur greater complication costs com-
pared with MDI) (see Table 7).
Sensitivity Analysis
Sensitivity analyses showed that the ﬁndings in US adults with
T1DM were most sensitive to changes in HbA1c, hypoglycemia
rates, fear of hypoglycemia, cost of severe hypoglycemia, and a
4-year pump life (See Table 8). Altering the improvement in
HbA1c levels associated with CSII compared with MDI from
1.2% in the base case to 0.95% (reported by Weissberg-Benchell
et al. [3]), and to 0.51% (as reported by Pickup et al. [2]), in-
creased the incremental cost-effectiveness ratios (ICERs) to
$US21,493/QALY and $US39,384/QALY, respectively. Recent
publications have suggested that CSII may be associated with
lower rates of hypoglycemia than MDI, with a 50% to 74%
reduced incidence of hypoglycemia [9,11–14]. Keeping the
hypoglycemia rates the same in both groups (0% increase)
resulted in an ICER of $US27,721/QALY, while reducing the
hypoglycemia rate in the CSII treatment arm by 75% led to an
improvement in the ICER to $US11,189/QALY compared with
MDI. Adding a disutility for fear of hypoglycemia provided an
ICER of $US11,647. Altering the cost of severe hypoglycemia to
that reported by O’Brien and colleagues led to an ICER of
$US23,225/QALY [25]. Replacement of an insulin pump every 4
years led to an ICER of $US26,230/QALY. Although this was
signiﬁcantly higher than the base case of 7 years, this still is well
within the acceptable range for cost-effectiveness in the United
States.
Exploratory Analysis: Child/Young Adult T1DM
Patients in the United States
LE and Quality-Adjusted Life Expectancy
In the base case analysis, T1DM treatment with CSII was pro-
jected to improve discounted LE and QALY gained by 0.695 and
0.799 years, respectively, compared with MDI. Mean (SD)
discounted LE was 20.827  0.238 years for CSII and
20.132  0.194 years with MDI. Mean (SD) discounted
QALYs were 14.418  0.199 years for CSII and 13.618  0.143
years with MDI (see Table 9). Calculation of undiscounted LE
produced values of 36.495  0.238 years in the CSII group and
34.480  0.194 years in the MDI arm (a difference of 2.02
years). Calculation of undiscounted QALYs produced values of
24.392  0.199 years in the CSII group and 22.564  0.143
years in the MDI arm (a difference of 1.83 QALY).
Table 6 Diabetes complications for adult type 1 diabetes patients in the United States: CSII versus MDI
Body system Complication
Incidence SD (%) Relative risk
(CSII vs. MDI)
Number needed to
treat (CSII vs. MDI)CSII MDI
Eyes Proliferative diabetic retinopathy 24.489 1.951 34.558 1.382 0.708 9
Cataract 19.911 1.329 18.446 1.284 1.079 —
Macular edema 53.127 1.534 54.314 1.562 0.978 84
Severe vision loss 40.163 1.566 41.061 1.530 0.977 111
Renal Microalbuminuria 70.978 2.101 78.518 1.345 0.904 13
Gross proteinuria 53.605 2.637 65.775 1.475 0.815 8
End-stage renal disease 21.037 1.579 26.238 1.424 0.802 19
Nephropathy death 15.851 1.422 20.613 1.395 0.783 21
Cardiovascular Myocardial infarction 26.098 1.416 27.481 1.361 0.950 72
Myocardial infarction death 14.825 1.153 15.481 1.193 0.957 152
Stroke event 9.203 0.957 7.862 0.835 1.170 —
Stroke death 3.359 0.603 2.814 0.508 1.194 —
Congestive heart failure 25.146 1.364 22.659 1.264 1.109 —
Congestive heart failure death 11.939 1.045 10.205 0.995 1.170 —
Peripheral vascular disease 13.158 1.121 15.552 1.089 0.839 41
Angina 11.918 1.069 9.935 0.998 1.199 —
Extremities Peripheral neuropathy 94.368 0.868 96.635 0.565 0.976 44
Foot ulcer 58.562 1.160 59.537 1.555 0.984 102
Recurring foot ulcer 87.894 4.983 88.325 4.991 0.995 232
Amputation from foot ulcer 19.014 1.465 19.378 1.407 0.981 274
Amputation from recurring foot ulcer 7.901 1.167 7.951 1.143 0.994 2000
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections.
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Incidence of Complications
Improved glycemic control associated with CSII treatment com-
pared with MDI led to a lower incidence of several key compli-
cations from diabetes over patients’ lifetimes. In regards to eye
disease, the cumulative incidence of proliferative diabetic retin-
opathy was reduced by 21% compared with MDI over the
60-year simulation period (RR = 0.79). The corresponding NNT
for proliferative diabetic retinopathy was 18 patients; suggesting
that only 18 patients need to be treated with CSII to avoid one
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Figure 1 Scatterplot for QALY comparing CSII versus MDI in adult type 1 diabetes patients in the United States.CSII, continuous subcutaneous insulin infusion;MDI,
multiple daily injections; QALY, quality-adjusted life-year.
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Figure 2 Cost-effectiveness acceptability curve for adult type 1 diabetes patients in the United States.
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case of proliferative diabetic retinopathy. In regard to ESRD, the
cumulative incidence of ESRD was reduced by 15% compared
with MDI over the 60-year simulation period (RR = 0.85). Simi-
larly, the cumulative incidence of neuropathy death was reduced
by 18% compared with MDI (RR = 0.82). Corresponding NNT
for ESRD and neuropathy death were 24 and 27, respectively.
Finally, the ﬁndings for cardiovascular complications showed
that the cumulative incidence of peripheral vascular disease was
reduced by 13% compared with MDI over the 60-year simula-
tion period (RR = 0.87), with a NNT of 78 patients. Additional
observations for diabetes complications are shown in Table 10.
Costs and Cost-Effectiveness
The mean discounted lifetime direct medical costs associated
with CSII for T1DM in US children/young adults was projected
to be $US212,597  2,915 compared with $US190,862  2,891
for MDI treatment (see Table 9). The incremental difference in
costs of $US21,734 translates into a cost per LYG of $US31,259
with CSII therapy versus MDI. The cost per QALY gained was
$US27,195.
The resampling simulation data were placed on a scatter plot
based on QALYs gained and included as Figure 3. The data were
then plotted on an acceptability curve to assess the likelihood of
cost-effectiveness according to willingness to pay in the United
States. Setting the willingness to pay at $US50,000/QALY, the
analysis demonstrated that CSII had a 93.8% probability of
being cost-effective for child/young adult T1DM patients using
QALYs gained as the outcome measure. (See Fig. 4)
The breakdown of total direct medical costs showed that
treatment costs were the greatest component. Mean lifetime
treatment costs were $US109,440 in the CSII group compared
Table 7 Breakdown of direct medical costs over patients’ lifetimes (adults)
Cost (per patient) CSII MDI Difference
Total direct medical costs ($US) 204,192 (2,950) 186,170 (3,159) 18,023
Treatment costs (index medication) ($US) 103,386 69,247 34,139
Management costs (concomitant medications and screening) ($US) 12,895 12,503 392
Complication costs ($US) 87,911 104,420 -16,509
CVD 14,776 14,446 330
Renal 19,939 26,689 -6,750
Ulcer/amp/neuropathy 22,853 24,540 -1,687
Eye 13,189 13,406 -217
Hypoglycemia 11,844 20,297 -8,453
Keto/lactic acidosis 5,310 5,042 268
Values shown are means with SDs in parentheses.
CSII, continuous subcutaneous insulin infusion; CVD, cardiovascular disease; MDI, multiple daily injections.
Table 8 Summary of sensitivity analysis results for adult patients with type 1 diabetes in the United States
Analysis
QALY (years) Total lifetime costs ($US 2007)
ICERCSII MDI CSII MDI
Base case (-1.2% 0.2% HbA1c for CSII compared with MDI) [3] 12.848 0.197 11.788 0.107 204,192 2,950 186,170 3,159 $16,992
HbA1c setting no. 2 (-0.95% 0.15% HbA1c for CSII compared with MDI) [3] 12.647 0.152 11.788 0.107 204,645 3,041 186,170 3,159 $21,493
HbA1c setting no. 3 (-0.51% 0.24% HbA1c for CSII compared with MDI) [2] 12.273 0.207 11.788 0.107 205,305 2,982 186,170 3,159 $39,384
No difference in hypoglycemia rates 12.753 0.200 11.788 0.107 212,942 3,009 186,170 3,159 $27,721
Hypoglycemia rates reduced by 75% 12.899 0.203 11.788 0.107 198,603 2,929 186,170 3,159 $11,189
Fear of hypoglycemia 11.448 0.171 10.433 0.101 198,790 2,972 186,967 2,858 $11,647
Conservative rate for cost of severe hypoglycemia ($273.89) [25] 12.830 0.199 11.773 0.110 194,989 2,897 170,440 3,059 $23,225
0% discount rate 20.318 0.425 18.153 0.225 380,120 7,300 339,173 7,272 $18,910
6% discount rate 9.060 0.108 8.454 0.060 126,840 1,613 116,475 1,706 $17,085
No effect on BMI 12.854 0.198 11.788 0.107 204,243 3,034 186,170 3,159 $16,943
Change in BMI = +1.59 12.828 0.205 11.773 0.110 204,217 3,085 186,170 3,159 $17,106
QOL for major hypo event and for all hypo event (Currie et al.) [23] 12.851 0.197 11.792 0.107 204,192 2,950 186,170 3,159 $17,023
4-year pump life 12.848 0.197 11.788 0.107 213,991 2,994 186,170 3,159 $26,230
6-year pump life 12.848 0.197 11.788 0.107 206,370 2,960 186,170 3,159 $19,045
8-year pump life 12.848 0.197 11.788 0.107 202,560 2,943 186,170 3,159 $15,452
BMI, body mass index;CSII, continuous subcutaneous insulin infusion; ICER, incremental cost-effectiveness ratio for CSII versus MDI, expressed in cost ($US 2007) per QALY saved;MDI,multiple
daily injections; QALY, quality-adjusted life-year; QOL, quality of life.
Table 9 Summary results for child/young adult type 1 diabetes patients in the United States: CSII versus MDI base case
CSII MDI
Difference between
CSII and MDI
Life expectancy (years) 20.827 0.238 20.132 0.194 0.695
Quality-adjusted life expectancy (years) 14.418 0.199 13.618 0.143 0.799
Total direct costs ($US 2007) $212,597 2,915 $190,862 2,891 $21,734
Costs/life expectancy ($US 2007 per life-year gained) $31,259
Costs/QALY ($US 2007 per QALY gained) $27,195
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections; QALY, quality-adjusted life-year.
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with $US71,804 for MDI. Complication and other management
costs were $US15,901 lower for CSII compared with MDI
($US103,157 vs. $US119,058, respectively). Therefore, the extra
treatment costs associated with CSII were partially offset by the
reduction in diabetes complications compared with MDI, even
when taking into account the survival paradox (that patients live
longer with CSII treatment, and therefore should experience
more complications and incur greater complication costs com-
pared with MDI) (see Table 11).
Sensitivity Analysis
Sensitivity analyses showed that the ﬁndings in US child/young
adult patients with T1DM were most sensitive to changes in
Table 10 Diabetes complications for child/young adult type 1 diabetes patients in the United States: CSII versus MDI
Body system Complication
Incidence SD (%) Relative risk
(CSII vs. MDI)
Number needed to
treat (CSII vs. MDI)CSII MDI
Eyes Proliferative diabetic retinopathy 21.154 1.665 26.652 1.469 0.794 18
Cataract 23.415 1.329 22.291 1.358 1.050 —
Macular edema 52.565 1.518 53.247 1.595 0.987 146
Severe vision loss 42.961 1.504 43.063 1.552 0.997 980
Renal Microalbuminuria 72.426 1.939 77.793 1.427 0.931 18
Gross proteinuria 55.021 2.458 63.404 1.659 0.867 11
End-stage renal disease 22.573 1.570 26.682 1.477 0.846 24
Nephropathy death 17.102 1.377 20.800 1.384 0.822 27
Cardiovascular Myocardial infarction 19.244 1.274 19.799 1.185 0.971 180
Myocardial infarction death 10.767 0.995 11.097 0.952 0.970 303
Stroke event 5.603 0.734 5.038 0.702 1.112 —
Stroke death 2.069 0.447 1.823 0.428 1.135 —
Congestive heart failure 19.032 1.279 17.741 1.201 1.073 —
Congestive heart failure death 8.018 0.853 7.301 0.826 1.098 —
Peripheral vascular disease 8.841 0.926 10.129 0.926 0.873 78
Angina 8.158 0.897 7.220 0.795 1.130 —
Extremities Peripheral neuropathy 94.471 0.811 95.965 0.618 0.984 66
Foot ulcer 63.763 1.605 64.473 1.529 0.988 140
Recurring foot ulcer 102.224 5.534 102.914 5.539 0.993 144
Amputation from foot ulcer 21.827 1.429 22.039 1.573 0.990 471
Amputation from recurring foot ulcer 10.060 1.329 10.209 1.353 0.985 671
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections.
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Figure 3 Scatterplot for QALY comparing CSII versus MDI in child/young adult type 1 diabetes patients in the United States. CSII, continuous subcutaneous insulin
infusion; MDI, multiple daily injections; QALY, quality-adjusted life-year.
682 St Charles et al.
HbA1c, hypoglycemia rates, fear of hypoglycemia, and a 4-year
pump life (See Table 12). Altering the improvement in HbA1c
levels associated with CSII compared with MDI from -0.9% in
the base case to -1.125% and to -0.675% altered the ICERs to
$US20,997/QALY and $US37,326/QALY, respectively. Recent
publications have suggested that CSII may be associated with
lower rates of hypoglycemia than MDI, with a 50% to 74%
reduced incidence of hypoglycemia [9,11–14]. To test this un-
certainty, hypoglycemia rates were assumed to be equivalent
between CSII and MDI and also assumed a 75% reduction in the
CSII treatment arm. Keeping the hypoglycemia rates the same in
both groups resulted in an ICER of $US45,595/QALY, while
reducing the hypoglycemia rate in the CSII treatment arm by
75% led to an improvement in the ICER to $US17,673/QALY
compared with MDI. Adding a disutility for fear of hypoglyce-
mia provided an ICER of $US19,300. Reducing the pump life to
4 years from 7 years in child/young adult with T1DM led to an
ICER of $40,652/QALY, suggesting that even if the insulin pump
is replaced more frequently, CSII is still cost-effective for child/
young adult T1DM patients in the United States.
Discussion
This study represents the ﬁrst cost-effectiveness analysis compar-
ing CSII with MDI in adult and child/young adult patients with
T1DM in the United States. Our study ﬁndings suggest that CSII
improves both mortality and morbidity for adult and child/young
adult patients with T1DM in the United States. Further, our
analysis suggests that CSII is a cost-effective medical intervention
for patients with T1DM. The study ﬁndings are important in that
the cost-effectiveness of CSII was compared with the use of MDI
with a newer insulin analogue and revealed ICERs well under the
$50,000 threshold often cited in studies using a US perspective
[26].
Treatment with CSII in adult patients with T1DM was asso-
ciated with improvements of 0.987 and 1.061 years in dis-
counted life-years gained and QALYs, respectively, compared
with MDI. Additionally, treatment with CSII in child/young adult
patients with T1DM was associated with improvements of 0.695
and 0.799 years in discounted life-years gained and QALY,
respectively, compared with MDI. Total lifetime costs were
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Figure 4 Cost-effectiveness acceptability curve for child/young adult type 1 diabetes patients in the United States.
Table 11 Breakdown of direct medical costs over patients’ lifetimes (child/young adult)
Cost (per patient) CSII MDI Difference
Total direct medical costs ($US) 212,597 (2,915) 190,862 (2,891) 21,734
Treatment costs (index medication) ($US) 109,440 71,804 37,636
Management costs (concomitant medications and screening) ($US) 14,016 13,745 271
Complication costs ($US) 89,141 105,313 -16,172
CVD 9,216 9,036 180
Renal 22,566 27,865 -5,299
Ulcer/amp/neuropathy 23,381 24,716 -1,335
Eye 13,881 13,839 42
Hypoglycemia 14,252 24,208 -9,956
Keto/lactic acidosis 5,845 5,649 196
Values shown are means with SDs in parentheses.
CSII, continuous subcutaneous insulin infusion; CVD, cardiovascular disease; MDI, multiple daily injections.
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greater for CSII in patients with T1DM in the United States when
compared with MDI for both adults and children/young adults.
Examining direct costs only, treatment costs were always greater
with CSII therapy, but these were partially offset by reduced costs
of complications from diabetes compared with MDI. Our ﬁnd-
ings led to ICERs of $US18,268/LYG for adult patients with
T1DM and $US31,259/LYG for child/young adult patients with
T1DM, which are within the range of <$US50,000 often cited in
the literature representing good value for money in the United
States [26].
The use of CSII compared with MDI led to a reduction in
many diabetes-related complications. The majority of diabetes-
related complications that were part of this analysis favored the
use of CSII over MDI, with RR reductions ranging from 0.5% to
29.2% for adults and 0.2% to 20.6% for children/young adults.
Renal complications and eye complications showed the greatest
reductions for patients receiving CSII.
Several other studies have examined the cost-effectiveness of
insulin pump therapy. Scuffham and Carr performed a cost-
effectiveness study on insulin pump therapy within the United
Kingdom [27]. They focused solely on hypoglycemia and
ketoacidosis over an 8-year period. Their study found that CSII
is cost-effective in patients with severe and/or unpredictable
hypoglycemia requiring hospitalization more than twice a year. A
study performed by Colquitt and colleagues that used semi-
quantitative methods reached similar conclusions [28]. Roze
et al. evaluated adult patients using insulin pump therapy within
the UK using the CDM [5]. They reported ICERs of £27,477/
LYG and £25,648/QALY, demonstrating that insulin pump
therapy represents good value for money in the United Kingdom.
Findings from Cohen and colleagues in Australia also supported
the cost-effectiveness of CSII when compared with MDI in
both adults and children/young adults with T1DM, resulting in
ICERs of $A74,147QALY and $A74,661/QALY respectively
(threshold = $A76,000) [4].
The key assumptions within the CDMwere thoroughly tested
by performing multiple sensitivity analyses. In our analysis, cost-
effectiveness was highly sensitive to HbA1c changes, hypoglyce-
mia rates, and fear of hypoglycemia. Speciﬁcally, in adults with
T1DM, an HbA1c decrease of only 0.51% for CSII compared
with MDI was less cost-effective, with an ICER of $US 39,384,
but still well below the generally accepted threshold. There are
several publications showing a marked reduction in hypoglyce-
mia rates (50% to 75%) with CSII compared with MDI, and
recurrent hypoglycemia is one of the most common clinical indi-
cations for insulin pump therapy [9,11–14]. A 75% reduction in
hypoglycemic events resulted in an ICER of $US11,189/QALY
for adults and $US17,693/QALY ICER for children/young
adults. Further improvements in ICERs may also result with
newer insulin pump technologies becoming available with con-
tinuous glucose monitoring systems designed to further reduce
hypoglycemia events. These devices can help identify ﬂuctuations
that may otherwise be unrecognizable with standard HbA1c tests
and intermittent ﬁnger stick measurements. Finally, adding a
disutility for fear of hypoglycemia resulted in a 31% ICER
improvement to $US11,647 for adults and a 29% ICER
improvement to $19,300 for children/young adults. Lastly, our
results were somewhat sensitive to shorter lifespan of the insulin
pump; however, each ICER remained below the $50,000 thresh-
old value many deem cost-effective in the USA.
Research has found that a disutility may exist because of a fear
of injection, thus making CSII more attractive than MDI [29,30].
Although this disutility could not be included in our modeling
analysis, this variable may have led to amore substantial effect for
patients receiving CSII versus MDI if it was part of the analysis.
Reducing this barrier for patientsmay help to improve compliance
and in turn patient outcomes, supporting the use of CSII over
MDI. In addition, there are new values for HRQOL, suggesting
improved patient-reported outcomes with CSII over glargine or
NPH-based MDI regimens [31]. Nevertheless, most of these new
values for HRQOL have not been directly linked with utilities or
disutilities. Therefore, in the absence of these updated utility
inputs, our model outcomes may have underestimated the impact
of improved patient utilities for CSII compared with MDI.
Although some limitations exist, theWeissberg-Benchell meta-
analysis is an excellent source for data on insulin pump therapy
[3]. One limitation involves the time frame in which many of
studies were published, as a majority of the 52 studies included in
the meta-analysis were published before 1987, with relatively few
studies published following the DCCT in 1993. Therefore, many
studies that were part of this meta-analysis represent data on older
insulin device technology, including nonbuffered insulin used in
pumps that were less accurate and reliable thanmodern devices or
newer insulins. A growing body of evidence and our clinical
experience suggests that newer insulin pump devices available
today lead to lower rates of hypoglycemia than MDI.
One limitation of our study was that the base case analysis
only takes into account direct medical costs from a third-party
US payer perspective. The base case study does not include
nonmedical costs, such as lost productivity, transport costs, resi-
Table 12 Summary of sensitivity analysis results for child/young adult patients with type 1 diabetes in the United States
Analysis
QALY (years) Total lifetime costs ($US 2007)
ICERCSII MDI CSII MDI
Base-case (-0.9% 0.2% HbA1c for CSII compared with MDI).
Hypoglycemia rates reduced by 50%.
14.418 0.199 13.618 0.143 212,597 2,915 190,862 2,891 $27,195
HbA1c setting no. 2 (-1.125% 0.2% HbA1c for CSII compared with MDI) 14.614 0.201 13.618 0.143 211,766 2,814 190,862 2,891 $20,997
HbA1c setting no. 3 (-0.675% 0.2% HbA1c for CSII compared with MDI) 14.218 0.200 13.618 0.143 213,227 2,991 190,862 2,891 $37,326
Hypoglycemia rates reduced by 0% 14.316 0.200 13.618 0.143 222,677 2,933 190,862 2,891 $45,595
Hypoglycemia rates reduced by 75% 14.472 0.187 13.618 0.143 205,952 2,935 190,862 2,891 $17,673
Fear of hypoglycemia 12.773 0.167 11.999 0.119 205,221 2,811 190,289 3,058 $19,300
0% discount rate 24.392 0.483 22.564 0.339 429,931 7,990 382,735 7,364 $25,820
6% discount rate 9.802 0.100 9.378 0.074 126,342 1,494 113,234 1,541 $30,935
No effect on BMI 14.417 0.199 13.618 0.143 212,521 2,826 190,682 2,891 $27,103
QOL for major hypo event and for all hypo event (Currie et al.) [23] 14.421 0.199 13.618 0.143 212,597 2,915 190,862 2,891 $27,273
4-year pump life 14.418 0.199 13.618 0.143 223,353 2,960 190,862 2,891 $40,652
6-year pump life 14.418 0.199 13.618 0.143 214,987 2,924 190,862 2,891 $30,185
8-year pump life 14.418 0.199 13.618 0.143 210,804 2,901 190,862 2,891 $24,952
BMI, body mass index;CSII, continuous subcutaneous insulin infusion; ICER, incremental cost-effectiveness ratio for CSII versus MDI, expressed in cost ($US 2007) per QALY saved;MDI,multiple
daily injections; QALY, quality-adjusted life-year; QOL, quality of life.
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dential aged or nursing care, and intangible costs, and therefore
is likely to underestimate total costs from a complete societal
perspective. A further limitation of modeling studies is that the
data used to design most models are primarily from clinical trials.
As a result, many real-life factors, such as compliance, effective-
ness, and treatment drop-out rates may not be taken into
consideration, as clinical trials often represent a “best-case
scenario.” HRQOL estimates provided by most studies reﬂect
changes associated with long-term complications rather than
with the treatment modality, per se. A further limitation of our
study was the lack of applicability to certain key patient sub-
groups (e.g., hypoglycemia-prone T1DM patients) that could be
a subject for future analyses and study.
An additional limitation of this study surrounds the explor-
atory analysis that compared the cost-effectiveness of MDI versus
CSII in children and young adults with T1DM. The methods for
this analysis included the use of ﬁndings from Doyle and col-
leagues, which included only 32 patients ranging in age from 8 to
21 years. Thus, the small number of patients provided little for
extrapolation of the data or reliability of the ﬁndings. Neverthe-
less, this study was the ﬁrst direct evaluation comparing the use
of glargine-based analogue MDI versus CSII therapy in youth,
with T1DM using a randomized, prospective study design and a
short time frame, making it of interest to payers to get some
guidance on the cost-effectiveness in this age group. In addition
to the weaknesses in the Doyle study, many of the inputs for the
CDM for this child/young adult analysis were taken from the
adult cohort as they were unknown. These inputs (costs of com-
plications, rates of complication, etc.), which were extrapolated
from the adult cohort to the child/young adult cohort, may not
accurately represent this population. Thus, the ﬁndings for this
population should be considered speculative.
Modeling is a useful mathematical tool that allows for the
projection of long-term clinical outcomes and costs using the
best, often shorter-term, published clinical and epidemiological
data currently available. Every effort has been made to utilize the
most accurate and reproducible data sources in the present analy-
sis to provide a real-world simulation of adult T1DM in the
United States [7]. Moreover, during development of the CDM,
preference was given to epidemiological data sources to attempt
to overcome, when possible, the potential drawback of relying on
clinical studies only as data sources in a modeling analysis.
Our modeling analysis of CSII versus MDI for T1DM in the
United States has demonstrated that improvements in glycemic
control attributed to CSII leads to improvements in LE and
QALYs because of the reduced incidence of diabetes-related com-
plications and side effects of therapy. CSII is associated with
ICERs for adult and child/young adult patients with T1DM of
$US 16,992 and $US27,195, respectively, representing good
value for money in the United States [26].
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